Iopofosine I 131 multiple dose for Small Lymphocytic Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Small Lymphocytic Lymphoma+8 MoreIopofosine I 131 multiple dose - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the effectiveness of iopofosine I 131 in treating patients with various types of B-cell malignancies.

Eligible Conditions
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Marginal Zone Lymphoma
  • Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Central Nervous System Lymphoma
  • Waldenstrom Macroglobulinemia
  • Multiple Myeloma

Treatment Effectiveness

Study Objectives

2 Primary · 9 Secondary · Reporting Duration: 3 years

12 months
Part B [CLOVER-WaM] Major Response Rate
135 days
Part A [CLOVER-1] Duration of Response
Part A [CLOVER-1] Overall Response Rate
Part A [CLOVER-1] Overall Survival
Part A [CLOVER-1] Progression Free Survival
Part B [CLOVER-WaM] Clinical Benefit Rate
Part B [CLOVER-WaM] Duration of Response
Part B [CLOVER-WaM] Overall Response Rate
Part B [CLOVER-WaM] Treatment Free Survival
3 years
Part A [CLOVER-1] Time to Next Treatment
84 days
Part A [CLOVER-1] Clinical benefit rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

8 Treatment Groups

CLR 131, intravenous administration CNS Lymphoma
1 of 8
CLR 131, intravenous administration WM
1 of 8
Iopofosine I 131, intravenous administration WM
1 of 8
Iopofosine I 131, intravenous administration CNS Lymphoma
1 of 8
CLR 131 intravenous administration NHL [CLOSED]
1 of 8
Iopofosine I 131, intravenous administration MM
1 of 8
Iopofosine I 131 intravenous administration NHL [CLOSED]
1 of 8
CLR 131, intravenous administration MM
1 of 8

Experimental Treatment

120 Total Participants · 8 Treatment Groups

Primary Treatment: Iopofosine I 131 multiple dose · No Placebo Group · Phase 2

CLR 131, intravenous administration CNS Lymphoma
Drug
Experimental Group · 1 Intervention: CLR 131 fractionated dose · Intervention Types: Drug
CLR 131, intravenous administration WMExperimental Group · 3 Interventions: CLR 131 single dose, CLR 131 multiple dose, CLR 131 fractionated dose · Intervention Types: Drug, Drug, Drug
Iopofosine I 131, intravenous administration WMExperimental Group · 3 Interventions: Iopofosine I 131 multiple dose, Iopofosine I 131 single dose, Iopofosine I 131 fractionated dose · Intervention Types: Drug, Drug, Drug
Iopofosine I 131, intravenous administration CNS Lymphoma
Drug
Experimental Group · 1 Intervention: Iopofosine I 131 fractionated dose · Intervention Types: Drug
CLR 131 intravenous administration NHL [CLOSED]Experimental Group · 3 Interventions: CLR 131 single dose, CLR 131 multiple dose, CLR 131 fractionated dose · Intervention Types: Drug, Drug, Drug
Iopofosine I 131, intravenous administration MMExperimental Group · 3 Interventions: Iopofosine I 131 multiple dose, Iopofosine I 131 single dose, Iopofosine I 131 fractionated dose · Intervention Types: Drug, Drug, Drug
Iopofosine I 131 intravenous administration NHL [CLOSED]Experimental Group · 3 Interventions: Iopofosine I 131 multiple dose, Iopofosine I 131 single dose, Iopofosine I 131 fractionated dose · Intervention Types: Drug, Drug, Drug
CLR 131, intravenous administration MMExperimental Group · 3 Interventions: CLR 131 single dose, CLR 131 multiple dose, CLR 131 fractionated dose · Intervention Types: Drug, Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years

Who is running the clinical trial?

Cellectar Biosciences, Inc.Lead Sponsor
14 Previous Clinical Trials
1,145 Total Patients Enrolled
John Friend, MDStudy DirectorCellectar Biosciences
1 Previous Clinical Trials
30 Total Patients Enrolled
Jarrod LongcorStudy DirectorCellectar Biosciences
2 Previous Clinical Trials
80 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have an estimated glomerular filtration rate of 30 mL/min/1.73 m2 or greater.
Hemoglobin ≥ 9 g/dL (last transfusion, if any, must be at least 1 week prior to study registration, and no transfusions are allowed between registration and dosing).